



Dear contributors, colleagues and co-workers,

In these difficult and challenging times I first of all want to express my wishes for your health and safety as well as that of your families, colleagues and friends. Secondly, I wish to give you a short update for the SENOMAC trial. We now have randomised **1916 patients** from five countries and await the upcoming safety analysis on May 12, 2020, with great interest.



Number of randomisations per month



Cumulative number of randomisations from start of trial


You should all have received an E-mail stating that patients who have been put on endocrine therapy while waiting for delayed surgery due to the situation caused by covid-19 are still regarded as candidates for inclusion in the trial as long as the endocrine therapy does not exceed 8 weeks prior to sentinel node biopsy. We have adopted the eCRF accordingly: please be aware that such endocrine therapy is not regarded as being neoadjuvant, and thus not reported as such. If anything is unclear please let me or your CRO know immediately.

Also due to the covid-19 situation and the travel restrictions that apply, monitoring visits have had to be postponed and will take place once the situation normalizes. In case of unclarified issues or questions, please contact your monitor directly. Likewise, we have accepted that follow-up visits may be temporarily replaced by mammography and telephone contact in order to protect our patients from potential risks.

As I have announced before, an independent safety analysis of all included patients will take place on May 12, 2020. I will be in touch as soon as decisions are taken and will communicate the results and consequences that will follow.

I thank you all for your fantastic efforts for the SENOMAC trial despite an immense work load for us all. Please do have a look at the **following table and figure, and please share this newsletter with your colleagues and co-workers.**

My best wishes for all,



Jana de Boniface,
for the SENOMAC steering committee and the sponsor Karolinska Institutet.
jana.de-boniface@ki.se or jana.de-boniface@capiostgoran.se

Table: Number of site-specific randomisations as of April 28, 2020

Please observe that this table only shows those sites that have generated randomisations as of 2020APR28. For a list of all initiated sites, please see the trial homepage.

| Site | Country | Initiation visit | First patient in | Number of randomisations |
|------------------------------------|---------|------------------|------------------|--------------------------|
| Karolinska | Sweden | 2015-01-30 | 2015-02-27 | 107 |
| Västerås | Sweden | 2015-03-02 | 2015-04-14 | 49 |
| S:t Göran | Sweden | 2015-03-05 | 2016-06-07 | 151 |
| Akademiska Uppsala | Sweden | 2015-03-12 | 2016-02-14 | 47 |
| Södersjukhuset | Sweden | 2015-03-18 | 2015-11-24 | 109 |
| Örebro | Sweden | 2015-03-25 | 2015-10-01 | 48 |
| Sahlgrenska | Sweden | 2015-04-23 | 2015-06-10 | 96 |
| Lund/Malmö | Sweden | 2015-05-13 | 2015-10-13 | 101 |
| Helsingborg | Sweden | 2015-05-20 | 2015-07-23 | 41 |
| Linköping | Sweden | 2015-05-27 | 2016-11-03 | 83 |
| Karlstad | Sweden | 2015-05-28 | 2015-12-14 | 36 |
| Lidköping/Skövde | Sweden | 2015-06-04 | 2015-10-22 | 72 |
| Uddevalla | Sweden | 2015-06-04 | 2015-09-21 | 23 |
| Kalmar | Sweden | 2015-09-02 | 2016-03-03 | 16 |
| Västervik | Sweden | 2015-09-02 | 2016-02-18 | 30 |
| Karlskrona | Sweden | 2015-09-03 | 2015-12-14 | 6 |
| Gävle | Sweden | 2015-09-10 | 2015-12-30 | 38 |
| Sundsvall | Sweden | 2015-10-15 | 2015-10-29 | 51 |
| Umeå | Sweden | 2015-11-19 | 2016-02-10 | 43 |
| Halmstad/Varberg | Sweden | 2015-12-10 | 2016-02-17 | 27 |
| Växjö | Sweden | 2016-01-14 | 2016-03-23 | 34 |
| Aarhus | Denmark | 2016-11-28 | 2017-04-25 | 88 |
| Randers | Denmark | 2017-09-14 | 2017-11-07 | 18 |
| Köpenhamn Rigshospitalet/Herlev | Denmark | 2016-12-19 | 2017-04-20 | 181 |
| Jönköping | Sweden | 2017-01-20 | 2017-11-13 | 33 |
| Kristianstad | Sweden | 2017-03-20 | 2017-05-17 | 36 |
| Borås | Sweden | 2017-02-20 | 2018-09-14 | 7 |
| Aabenraa | Denmark | 2017-10-12 | 2017-12-13 | 50 |
| Odense | Denmark | 2017-11-22 | 2018-02-16 | 34 |
| Esbjerg | Denmark | 2017-12-12 | 2018-03-05 | 8 |
| Viborg | Denmark | 2017-11-03 | 2018-03-16 | 50 |
| Aalborg | Denmark | 2017-10-10 | 2018-02-07 | 61 |
| Bad Langensalza | Germany | 2018-04-04 | 2018-05-23 | 4 |
| Rostock | Germany | 2018-03-12 | 2018-06-07 | 11 |
| Berlin Spandau | Germany | 2018-04-19 | 2018-09-07 | 3 |
| Laiko 1, Athens | Greece | 2018-06-28 | 2018-10-12 | 9 |

| | | | | |
|------------------------|---------|------------|------------|-------------|
| Vejle | Danmark | 2018-03-19 | 2018-11-07 | 36 |
| Esslingen | Germany | 2018-02-16 | 2018-10-26 | 2 |
| Klinikum Kassel | Germany | 2018-06-12 | 2018-11-22 | 1 |
| Heraklion, Crete | Greece | 2019-02-19 | 2019-03-07 | 7 |
| Athens Euroclinic | Greece | 2019-12-11 | 2019-02-12 | 5 |
| Dresden | Germany | 2018-05-02 | 2019-03-01 | 5 |
| Hanau | Germany | 2018-05-18 | 2019-02-12 | 8 |
| Karlsruhe | Germany | 2018-07-11 | 2018-12-18 | 1 |
| Villingen-Schwenningen | Germany | 2018-09-10 | 2018-12-28 | 1 |
| Mittelbaden | Germany | 2018-08-16 | 2019-03-13 | 3 |
| Laiko 2, Athens | Greece | 2018-11-07 | 2019-05-29 | 4 |
| San Raffaele Milano | Italy | 2018-02-01 | 2019-05-21 | 4 |
| IEO Milano | Italy | 2019-05-06 | 2019-06-06 | 16 |
| Unna | Germany | 2018-03-01 | 2019-05-28 | 5 |
| Ebersberg | Germany | 2018-04-10 | 2019-04-06 | 2 |
| Stendal | Germany | 2018-04-25 | 2019-05-14 | 1 |
| Wiesbaden St. Josef | Germany | 2018-06-14 | 2019-05-03 | 1 |
| Worms | Germany | 2018-08-28 | 2019-05-02 | 1 |
| Potsdam | Germany | 2019-06-18 | 2019-07-01 | 3 |
| Tübingen | Germany | 2019-09-04 | 2019-09-24 | 6 |
| Böblingen | Germany | 2018-07-10 | 2019-11-07 | 1 |
| Wiesbaden Asklepios | Germany | | | 2 |
| Total | | | | 1916 |

Figure: Accumulated site-specific inclusion (only sites generating randomisations as of April 28, 2020 are shown).

